<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992339</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-010-DLBCL-001</org_study_id>
    <nct_id>NCT03992339</nct_id>
  </id_info>
  <brief_title>A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <acronym>SEARCH</acronym>
  <official_title>An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antengene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antengene Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm, and registered study of ATG-010 in Patients with&#xD;
      Relapsed/Refractory Diffuse Large B-Cell Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single arm, and registered study. About 60 patients with&#xD;
      relapsed/refractory DLBCL plan to be enrolled in about 10 study sites of the study. It is&#xD;
      planned that at least 50% (~30 patients) will have the GCB subtype of DLBCL. Enrolled&#xD;
      patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4&#xD;
      week (28-day) a cycle. Patients should remain on the study treatment of ATG-010, until either&#xD;
      PD or occurrence of unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage of subjects with PR, or CR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of time from first occurrence of CR or PR until the first date that disease progression is objectively documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of patients who achieve CR, PR, or SD for a minimum of 4 weeks, following the first dose of study drug (i.e., CR+PR+SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of time from the first dose of study drug until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of time from the first dose of study drug until progression or death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</condition>
  <arm_group>
    <arm_group_label>ATG-010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle</intervention_name>
    <description>Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.</description>
    <arm_group_label>ATG-010</arm_group_label>
    <other_name>Selinexor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must provide informed consent form (ICF) prior to the first screening&#xD;
             procedure.&#xD;
&#xD;
          2. Age ≥18 years.&#xD;
&#xD;
          3. ECOG performance status of ≤ 2.&#xD;
&#xD;
          4. Patients should have estimated life expectancy of &gt;3 months at study entry.&#xD;
&#xD;
          5. Previously treated, pathologically confirmed de novo DLBCL, or DLBCL transformed from&#xD;
             previously diagnosed indolent lymphoma (e.g., follicular lymphoma).&#xD;
&#xD;
          6. Patients must have received at least 2 but no more than 5 previous systemic regimens&#xD;
             for the treatment of their de novo or transformed DLBCL.&#xD;
&#xD;
          7. Documented clinical or radiographic evidence of progressive DLBCL prior to dosing.&#xD;
&#xD;
          8. Patients must have measurable disease per the revised criteria for response assessment&#xD;
             of lymphoma (Cheson, 2014). Lymph nodes should be considered abnormal if the long axis&#xD;
             is &gt; 1.5 cm, regardless of the short axis. If a lymph node has a long axis of 1.1 to&#xD;
             1.5 cm, it should only be considered abnormal if its short axis is &gt; 1.0. Lymph nodes&#xD;
             ≤ 1.0 by ≤ 1.0 will not be considered abnormal for relapse or PD.&#xD;
&#xD;
          9. Patients must not be eligible for high-dose chemotherapy with autologous stem cell&#xD;
             transplantation rescue.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are pregnant or lactating.&#xD;
&#xD;
          2. DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma&#xD;
             (Hodgkin's lymphoma +NHL), or DLBCL transformed from diseases other than indolent NHL&#xD;
             or Richter's.&#xD;
&#xD;
          3. Primary mediastinal (thymic) large B-cell lymphoma.&#xD;
&#xD;
          4. Known central nervous system lymphoma or meningeal involvement.&#xD;
&#xD;
          5. Patients whose most recent systemic anticancer therapy include radiation,&#xD;
             chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy&#xD;
             other than glucocorticoids &lt; 6 weeks prior to first dose of study drug.&#xD;
&#xD;
          6. Patients who have not recovered to Grade ≤ 1 clinically significant adverse events, or&#xD;
             to their baseline, from their most recent systemic anti-DLBCL therapy.&#xD;
&#xD;
          7. Patients with active graft-versus-host disease after allogeneic stem cell&#xD;
             transplantation. At least 4 months must have elapsed since completion of allogeneic&#xD;
             stem cell transplantation.&#xD;
&#xD;
          8. Major surgery within 2 weeks of first dose of study treatment of ATG-010.&#xD;
&#xD;
          9. Any life-threatening illness, medical condition or organ system dysfunction which, in&#xD;
             the Investigator's opinion, could compromise the patient's safety.&#xD;
&#xD;
         10. Unstable cardiovascular function:&#xD;
&#xD;
               1. Symptomatic ischemia, or&#xD;
&#xD;
               2. Uncontrolled clinically significant conduction abnormalities (i.e., ventricular&#xD;
                  tachycardia on anti-arrhythmia are excluded; First degree atrioventricular block&#xD;
                  or asymptomatic left anterior fascicular block /right bundle branch block will&#xD;
                  not be excluded), or&#xD;
&#xD;
               3. Congestive heart failure of New York Heart Association Class ≥3, or&#xD;
&#xD;
               4. Myocardial infarction within 3 months.&#xD;
&#xD;
         11. Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics,&#xD;
             antivirals, or antifungals within 1 week prior to first dose; however, prophylactic&#xD;
             use of these agents is acceptable even if parenteral.&#xD;
&#xD;
         12. Active hepatitis B virus or hepatitis C virus infection.&#xD;
&#xD;
         13. Known human immunodeficiency virus infection.&#xD;
&#xD;
         14. Patients unable to swallow tablets, patients with malabsorption syndrome, or any other&#xD;
             gastrointestinal disease or gastrointestinal dysfunction that could interfere with&#xD;
             absorption of study treatment of ATG-010.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shan bing, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jasmine Sun, MD</last_name>
    <phone>13701803117</phone>
    <email>jasmine.sun@antengene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacey Chen, MD</last_name>
    <email>stacey.chen@antengene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqin Song, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yuqin Song, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmei Jing, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hongmei Jing, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingqing Cai, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Qingqing Cai, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Qingyuan Zhang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongping Song, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yongping Song, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liling Zhang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Liling Zhang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Zhou, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hui Zhou, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affilate Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huayuan Zhu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Huayuan Zhu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Chang chun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sujun Gao, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sujun Gao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Zhang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yang Zhang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junning Cao, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Junning Cao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liqun Zou, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Liqun Zou, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin blood research institute</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tingyu Wang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tingyu Wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanfang Li, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Lanfang Li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of the University of the Chinese Academy of Sciences</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Yang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Haiyan Yang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

